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ICE inhibitor YVADcmk is a potent therapeutic agent against 
in vivo liver apoptosis
Nicolas Rouquet*, Jean-Christophe Pagès*, Thierry Molina†, 
Pascale Briand* and Virginie Joulin*
In liver, apoptosis is a physiological process involved in
the clearance of injured cells and in homeostatic
control [1]. However, in patients with viral fulminant
hepatitis or with nonacute liver diseases [2], dramatic
liver failure or secondary cirrhosis results from the
death of hepatocytes, which express the cell-surface
receptor Fas, by apoptosis. To date, treatment of
fulminant hepatitis relies mainly on orthotopic liver
transplantation, which is limited by immunological
complications and graft availability. Unravelling the
molecular mechanisms that underlie acute liver failure
could allow the design of an appropriate therapy.
Ligand-bound Fas and tumour necrosis factor a (TNF-a)
induce hepatic apoptosis in mice [3–6]. In various cell
types, Fas- or TNF-a-induced apoptosis is blocked by
viral proteins (such as p35 and CrmA) as well as by a
decoy peptide (YVADcmk) [7–11], suggesting that these
mechanisms of apoptosis involve ICE (interleukin-1 b
converting enzyme)-like proteases. Here, we report
that, in vivo, pre-treatment of mice with YVADcmk
protects them from the lethal effect of anti-Fas
antibody and from liver failure induced by injection of
TNF-a. Remarkably, YVADcmk administration is also
highly effective in rescuing mice that have been
pretreated with anti-Fas antibody from rapid death,
despite extensive hepatic apoptosis. This dramatic
curative effect could be of clinical benefit for the
treatment of viral and inflammatory liver diseases.
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Results and discussion
ICE-like proteases, mammalian homologs of the nematode
cell death protein Ced-3, have apoptotic properties when
overexpressed in various cell lines [12–19]. In vitro, the
inhibition of these proteases by certain viral proteins, as
well as by the YVADcmk peptide [7], results in protection
against TNFa- and Fas-mediated apoptosis [8–11,20,21].
Primary cultured mouse hepatocytes undergo apoptosis
after incubation with anti-Fas antibody in combination
with cycloheximide (CHX) [22,23]. To investigate the role
of ICE-like proteases in Fas-mediated apoptosis, primary
hepatocytes were incubated with YVADcmk and then
treated with anti-Fas antibody supplemented with CHX.
In the absence of YVADcmk, 90 % of the cells had under-
gone apoptosis after 36 hours of incubation with anti-Fas
antibody, whereas more than 90 % of the cells were resis-
tant to Fas-induced apoptosis in the presence of 200 mM
YVADcmk, even after a 60 hour incubation (Fig. 1a,b).
The addition of YVADcmk inhibited apoptosis in a dose-
dependent manner (Fig. 1c,d): in the presence of 50 mM
YVADcmk, 50 % of the cells treated with anti-Fas anti-
body died within 24 hours; in the presence of 300 mM
YVADcmk, 100 % of the cells survived. Note that
YVADcmk was diluted in DMSO, which is known to act
as a differentiating agent for primary cultures of hepato-
cytes; at the concentrations used here, however, DMSO
per se conferred no protective effect against Fas-mediated
apoptosis (data not shown).
The intraperitoneal or intravenous administration of anti-
Fas antibody in mice leads to death [3]. That this results
from severe liver damage was shown by the liver-specific
expression of a Bcl-2 transgene, which prevented the
lethal effects of the antibody [24]. To evaluate the effect
of ICE inhibitor on Fas-mediated apoptosis in vivo, mice
were treated with YVADcmk (4 mmole) 2 hours before
injection of anti-Fas antibody. Most of the mice (93 %)
survived and were healthy, whereas all untreated mice
died 3–4 hours after antibody injection (Fig. 2a). Histolog-
ical tissue sections of surviving mice were examined for
liver damage and regenerative features. The livers of
YVADcmk-treated mice were protected against lethal
hepatic cytolysis, but had many areas of hepatocyte injury
12 and 24 hours after antibody injection. This damage
consisted of numerous typical apoptotic bodies sur-
rounded by polynuclear granulocyte, lymphocyte and
macrophage infiltrates; no such damage was seen in
control mice (treated with YVADcmk but not exposed to
anti-Fas antibody; data not shown). The anti-apoptotic
properties of YVADcmk in vivo were confirmed by the
TUNEL assay (terminal deoxynucleotidyl transferase
(TdT)-mediated dUTPbiotin nick end-labeling), which
detects DNA fragmentation — a hallmark of apoptosis. By
1.5 hours after anti-Fas antibody injection, the livers of
unprotected mice had numerous TUNEL-positive cells
(Fig. 3a), whereas the extent of the apoptosis was reduced
significantly in livers from YVADcmk-protected mice (Fig.
3b). Mitoses appeared in the parenchyma without any
obvious zonal distribution within 1 day and persisted at
day 4 (Fig. 3c). Progressively, apoptotic bodies disappeared
within 6 days and, at day 13, liver architecture was indistin-
guishable from that of normal liver. Plasmatic transaminase
levels increased and then decreased progressively to reach
normal values concomitant with the disappearance of the
apoptotic process (data not shown). The increase in
transaminase levels during this process, a process which is
usually described as a nonlytic event, probably results from
insufficient phagocytosis [3].
The duration of the YVADcmk protective effect was
tested by injecting anti-Fas antibody at day 1, 2 or 3 after
administration of YVADcmk. Only the mice injected at day
3 died, suggesting that the effect of YVADcmk was tran-
sient. Histological examination of liver, heart, lung, spleen,
thymus, lymph nodes, kidney and brain was performed in
three mice one month after a single YVADcmk treatment,
revealing no apparent cytotoxicity. Finally, the long-term
survival of protected mice confirms that blockage of ICE-
like proteases, and thereby inhibition of massive hepatic
apoptosis, is highly efficient in preventing lethality
induced by anti-Fas antibody injection.
TNF-a is a potent mediator of hepatocyte apoptosis and
liver failure [4,5]. As the signalling pathway of the TNF
type I-receptor requires an ICE-like protease [9,11], we
examined whether YVADcmk treatment could protect
against TNF-induced hepatocyte apoptosis and liver
damage. As shown above for Fas-induced apoptosis, addi-
tion of YVADcmk (200 mM) blocked TNF-induced apop-
tosis of primary hepatocytes, which occurred within 24
hours in the absence of YVADcmk (Fig. 1e,f). YVADcmk
protection against TNF-induced liver damage in vivo was
tested by injection of YVADcmk and TNF-a. As the in vivo
hepatic apoptosis mediated by TNF-a is known to require
transcriptional arrest [4], mice were co-treated with ActD.
The high dose (9 mg kg–1) of TNF-a injected into ActD-
sensitized mice induced liver damage (Fig. 3e) and death of
all the mice in less than 7 hours. Interestingly, YVADcmk
administered before TNF-a into ActD-sensitized mice
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Figure 2
In vivo protective effect of YVADcmk on Fas-
induced mortality. (a) Preventive effect of
YVADcmk. Mice were injected
intraperitoneally with YVADcmk 2 h before
intravenous injection of anti-Fas antibody
(open circles). (b) Curative effect of YVAD-
cmk. Mice were injected intraperitoneally with
YVAD-cmk 2 h after intravenous injection of
anti-Fas antibody (open circles). Control mice
received anti-Fas antibody alone (filled
squares and filled circles) or YVAD-cmk alone
(open squares).
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Figure 1
Effect of YVADcmk on Fas- and TNF-a-mediated
hepatocyte cytotoxicity in vitro. (a,b) Primary
mouse hepatocytes were incubated with anti-Fas
antibody in the presence (open bars and open
circles) or absence (filled bars and filled circles)
of YVAD-cmk. (c,d) Dose-dependent inhibition of
Fas-induced apoptosis by YVAcmk. Primary
hepatocytes were incubated for 24 h with various
concentrations of YVADcmk in the presence
(filled bars and filled circles) or absence (open
bars and open circles) of anti-Fas antibody. (e,f)
Primary hepatocytes were incubated with
recombinant murine TNF-a and actinomycin D
(ActD) in the presence (open bars and open
circles) or absence (closed bars and filled
circles) of YVADcmk. Control experiments
showed that YVADcmk solvent (DMSO) did not
interfere with hepatocyte apoptosis (see text).
Percent apoptotic hepatocytes (Hoechst
staining) and viability (blue trypan exclusion) were
obtained from triplicate experiments.
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blocked the appearance of liver damage characterized by
apoptosis (Fig. 3f) and prevented the death of animals.
Considering the wide range of cells sensitive to TNF cyto-
toxicity [25], the causal relationship between TNF-induced
death and TNF-induced liver damage has not yet been
demonstrated formally. The ability of YVADcmk to protect
against TNF-lethal cytotoxicity could thus be related to its
protection of other cell types in vivo. Note that inflamma-
tory response syndrome observed in septic shock is mainly
related to TNF-a production [26–28] and is attenuated in
ICE-deficient mice [29]. It will be thus of great interest to
assess the ability of YVADcmk to abolish multiple organ
failure in septic shock experimental models. 
To evaluate the curative potential of YVADcmk treatment
against Fas-induced liver damage, we tested its ability to
stop an ongoing lethal hepatic cytolysis. Time-course
analysis of hepatic histological damage induced by anti-Fas
antibody administration showed that 50–70 % of the liver
was destroyed within 2 hours (Fig. 3d). As this experimen-
tal damage could be relevant to clinical lesions observed
during liver failure [3], YVADcmk was administrated
2 hours after anti-Fas antibody injection. Under these con-
ditions, 86 % of the mice were rescued, whereas all animals
died in the control group, untreated with YVADcmk (Fig.
2b). It is noteworthy that YVADcmk treatment is rapidly
effective, considering the short survival of mice treated
with anti-Fas antibody (3–4 hours). Biochemical analysis of
hepatic transaminases and liver histology of rescued mice
showed apoptosis followed by a regenerative process
similar to that described for protected mice in the preven-
tive protocol (data not shown). These data demonstrate
that YVADcmk is able to overcome the rapid progression
of dramatic hepatic damage induced by Fas activation.
Our results suggest that in vivo inhibition of ICE-depen-
dent apoptosis mediated by Fas or TNF-a represents an
attractive approach for treating liver injuries, including
including those caused by inflammatory, viral and auto-
immune diseases [1]. As we can assume that, during fulmi-
nant hepatitis, multiple signals account for massive hepatic
destruction, it would be of interest to assess ICE-mediated
protection in other models. This hypothesis is supported
by our preliminary experiments demonstrating an in vivo
protective effect of YVADcmk against LPS-induced fulmi-
nant hepatitis (N.R. and A. Mignon, unpublished data).
Recently, transgenic liver-specific expression of Bcl-2 has
proven its efficacy in protecting mice against Fas-induced
lethality [24]. However, therapeutic application of Bcl-2
will encounter the difficulties inherent to gene-transfer
approaches. Our results provide evidence that a simple
galenic formulation of ICE-inhibiting drugs has a curative
effect on Fas-mediated liver apoptosis. This opens the
field for new treatments of viral fulminant hepatitis.
Materials and methods
In vitro experiments
Hepatocytes were isolated by in situ collagenase perfusion [23]. The per-
fused liver was minced, cells were suspended in M199 medium with 10 %
fetal calf serum (FCS; Gibco-BRL) and filtered through a 70 mm mesh filter.
Viability was over 90 % according to trypan blue exclusion. Cells were
counted and plated at a density of 5 × 105 cells per 35 mm dishes in M199
medium containing 10 % FCS. The cells were allowed to adhere for 3 h; the
medium was then removed and replaced by M199 containing 10–8 M
insulin, 10–6 M thyroid hormone and 10–6 M dexamethasone. The ex vivo
Figure 3
Liver sections from untreated and YVAD-cmk-treated mice. (a,b)
TUNEL in situ detection of apoptosis, ×250. (a) Liver section from a
YVADcmk-untreated mouse 1.5 h after intravenous injection of anti-Fas
antibody. Note the presence of multiple stained nuclei (arrows). (b)
Liver section from YVAD-cmk-pretreated mouse 1.5 h after intravenous
injection of anti-Fas antibody. Rare stained nuclei are detected
(arrows). (c,d) Histological analysis, ×200. (c) Liver section from
YVAD-cmk-pretreated mouse prepared 4 days after intravenous
injection of anti-Fas antibody. The liver has partially recovered its
normal organization, despite the presence of mononuclear cell
infiltrates and some hepatocyte mitosis. The same histological features
were observed with liver sections of rescued mice, which had received
YVAD-cmk 2 h after anti-Fas antibody injection. (d) Liver section from
untreated mouse prepared 2 h after a single intravenous injection of
anti-Fas antibody. The liver exhibits architectural disorganization,
numerous apoptotic bodies (arrows) and infiltration of blood cells. (e)
Liver section from untreated mice prepared upon death, 7 h after co-
injection of ActD and TNF-a. The liver section shows a total
disorganization of tissue architecture with numerous apoptotic bodies
(arrows). (f) Liver section from YVADcmk-treated mouse was
performed 7 h after injection of YVADcmk followed by ActD and
TNF-a. The liver displays few scattered apoptotic bodies.
protective effect of YVADcmk (Ac-Tyr-Val-Ala-Asp-chloromethylketone)
(Bachem Biochimie SARL, Bale) was explored by culturing primary hepato-
cytes in the presence or absence of 200 mM YVADcmk in dimethyl sulfox-
ide (DMSO). At the same time anti-Fas antibody (1 mg ml–1) (Pharmingen),
supplemented with 10 mg ml–1 CHX or recombinant murine TNF-a
(20 ng ml–1) (Genzyme) supplemented with ActD (333 nM) (Sigma) were
added. Cells were monitored at times up to 60 h and the percentage of
viable cells assessed by trypan blue exclusion. Approximately 200 cells
were counted in each sample. To monitor apoptosis, Hoechst 33258 stain-
ing was performed as described [23].
In vivo experiments
To explore the in vivo preventive effect of YVADcmk, a group of 14 mice
were injected intraperitoneally with YVADcmk (4 mmole in 200 ml PBS) 2 h
prior to intravenous injection of anti-Fas antibody (10 mg in 100 ml 0.9 %
NaCl) or prior to intravenous injection of 9 µg kg–1 of TNF-a and intraperi-
toneal administration of ActD (16 mg in 200 ml PBS). To explore the in vivo
curative effect of YVADcmk, a group of 7 mice were injected intraperi-
toneally with YVADcmk (4 mmole in 200 ml PBS) 2 h after intravenous injec-
tion of anti-Fas antibody (10 mg in 100 ml 0.9 % NaCl). As controls, 15 mice
received anti-Fas antibody alone (10 mg in 100 ml 0.9 % NaCl) and 3 mice
received YVADcmk alone (4 mmole in 200 ml PBS). 8-week-old B6D2/F1
mice were used in all experiments.
Histological examinations, TUNEL and serum analysis
Livers were excised and immediately transferred to Bouin’s and formalin-
acetic acid–alcohol fixatives. Samples embedded in Paraplast were cut at
5 mm and stained with hematoxylin and eosin. Using light microscopy, 3
fields of each sample were analyzed for typical apoptotic features: marked
condensation of chromatin, cell shrinkage and apoptotic bodies. Apoptosis
severity was evaluated by a ratio of the number of apoptotic hepatocytes to
the total hepatocytes of the field. The TUNEL procedure was performed
with the ‘In situ cell death detection kit, POD’ (Boehringer Mannheim). For
serum analysis, biochemical parameters of the serum (ALT, alanine amino-
transferase, and AST, aspartate aminotransferase) were quantified using a
standard clinical automatic analyzer (Hitachi, Type 7150).
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